Aims: To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer. Patients & methods: The MTD was determined from dose ...

Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...

• Afatinib comes as a tablet which should be taken by mouth on an empty stomach preferably either two hours after a meal or one hour before a meal. • Never take afatinib tablets in smaller or ...

Out of the 319 patients who were randomised to afatinib or gefitinib, a significantly higher proportion responded to the first than the second (70.0% versus 56.0%; p=0.008) with a median duration ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations ...

LUX-Lung 3 results highlighted at the official ASCO Press Conference: Afatinib* delays cancer progression significantly more than the best standard chemotherapy Ingelheim, Germany, 4 June 2012 ...

Afatinib (Giotrif, Boehringer Ingelheim) is an irreversible tyrosine kinase inhibitor (TKI) that blocks the epidermal growth factor receptor (EGFR) ErbB1 and other members of the ErbB family. The ErbB ...

Afatinib is used to treat a certain type of lung cancer (non-small cell lung cancer). Gefitinib is used to treat lung cancer. This medication is used to treat lung cancer. Erlotinib is used to ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...